公开(公告)号：US20230102273A1

公开(公告)日：2023-03-30

申请号：US16088096

申请日：2017-03-27

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Kentaro IWATA ,  Masahiro MIZUNO ,  Kazuhiro MAEDA ,  Tsuneo YASUMA ,  Misaki HOMMA ,  Yuya OGURO ,  Naohiro TAYA ,  Lei ZHU ,  John Daniel BAILEY ,  Marianne LANGSTON ,  Siddhesh Dinanath PATIL ,  Shruti GOUR ,  Lilly ROY

IPC: C07D471/08 ,  A61K9/48

Abstract: The present disclosure relates to crystalline forms of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one hemihydrate (Compound 1) and/or tautomers thereof, wherein Compound 1 has the structure: (I).0.5H2O; processes for preparing crystalline forms of Compound 1 and/or tautomers thereof; pharmaceutical compositions comprising the crystalline forms; methods of inhibiting a cell division cycle 7 in a mammal comprising administering the crystalline forms; and methods of treating a cell division cycle 7 mediated cancer in a mammal comprising administering the crystalline forms or a pharmaceutical composition comprising the crystalline forms.